Immune Regulatory Targets in Therapeutic Monoclonal Antibodies: Mechanisms of the BAFF and PD-1 Pathways

The BAFF pathway and the PD-1 pathway represent two typical directions in immune regulation by therapeutic monoclonal antibodies. The BAFF pathway mainly regulates B-cell survival, maturation, and autoantibody production, making it suitable for studies related to autoimmunity and abnormal humoral immunity. The PD-1 pathway mainly regulates T-cell inhibition, exhaustion, and antitumor immune responses, making it suitable for studies of tumor immunity and immune functional recovery under chronic antigen stimulation.

Keywords: therapeutic monoclonal antibody; BAFF; BLyS; TNFSF13B; BAFF-R; TACI; BCMA; APRIL; PD-1; PD-L1; immune checkpoint; B cell; T cell; autoimmune disease; tumor immunity

1 Immune Regulatory Positioning of the BAFF and PD-1 Pathways

1.1 Basic Attributes of the Two Target Types

(1) BAFF pathway

BAFF, also known as B-cell activating factor or BLyS, is a member of the TNF superfamily. It mainly regulates B-cell survival, maturation, differentiation, and antibody production. When this pathway is abnormally enhanced, it can promote the survival of autoreactive B cells and increase the risk of autoantibody production. Therefore, it is often associated with systemic autoimmune diseases, abnormal B-cell activation, and antibody-mediated inflammation.

(2) PD-1 pathway

PD-1 is an inhibitory immune checkpoint molecule expressed on the surface of T cells. It mainly inhibits T-cell receptor signaling, reduces cytokine production, and restricts cytotoxic function by binding to PD-L1 or PD-L2. After tumor cells or cells in the tumor microenvironment upregulate PD-L1, they can use this pathway to reduce T-cell effector responses and thereby evade immune clearance.

(3) Differences in regulatory direction

BAFF-targeting antibodies are usually used to reduce abnormal B-cell survival signals and belong to immunosuppressive or immune-rebalancing strategies. PD-1/PD-L1-targeting antibodies are mostly used to release T-cell inhibition and belong to immune activation or immune restoration strategies. Both are control nodes of immune homeostasis, but they differ in target cells, pathological mechanisms, and therapeutic purposes.

1.2 Position in Disease Mechanisms

(1) BAFF favors humoral immune abnormalities

The BAFF pathway mainly affects the selective pressure and survival threshold of the B-cell pool. When BAFF levels increase, some autoreactive B cells that should normally be eliminated or silenced may gain a survival advantage and further participate in autoantibody production, immune complex formation, and tissue inflammation.

(2) PD-1 favors cellular immune suppression

The PD-1 pathway mainly limits T-cell activation and effector function. In the tumor microenvironment or chronic infection, persistent antigen stimulation can induce high PD-1 expression, driving T cells into a hyporesponsive or exhausted state characterized by reduced proliferative capacity, weakened cytotoxic activity, and decreased effector cytokine production.

(3) Differences in therapeutic strategies

The therapeutic focus of BAFF targeting is to reduce abnormal B-cell survival and autoantibody-driven pathological responses. The therapeutic focus of PD-1/PD-L1 targeting is to restore antigen-specific T-cell function. The former emphasizes reducing abnormal immune responses, while the latter emphasizes enhancing antitumor immune responses.

Table 1 Immune Regulatory Differences Between the BAFF Pathway and the PD-1 Pathway

Comparison Dimension	BAFF Pathway	PD-1 Pathway
Main immune cells	B cells, plasmablasts, plasma cell-related lineages	T cells, some NK cells, and exhaustion-like lymphocytes
Main function	Promotes B-cell survival, maturation, and antibody production	Inhibits T-cell activation and effector function
Pathological association	Autoantibodies, abnormal B-cell activation, humoral immune imbalance	Tumor immune escape, T-cell exhaustion, chronic antigen stimulation
Antibody action direction	Blocks BAFF signaling and reduces B-cell survival support	Blocks PD-1/PD-L1 inhibitory signaling and restores T-cell function
Typical therapeutic logic	Immunosuppression or immune rebalancing	Immune activation or release of immune inhibition

2 Composition and Mechanism of the BAFF Pathway

2.1 BAFF and Its Receptor System

(1) BAFF

BAFF is mainly produced by myeloid cells, dendritic cells, monocytes, macrophages, some stromal cells, and activated immune cells. Its expression level can be affected by inflammatory factors, type I interferons, Toll-like receptor signaling, and the tissue inflammatory microenvironment.

(2) BAFF-R

BAFF-R is the key receptor through which BAFF maintains mature B-cell survival. It mainly participates in peripheral B-cell survival, follicular B-cell maintenance, and B-cell homeostasis. When BAFF-R signaling is excessively strong, it may lower the threshold for eliminating autoreactive B cells.

(3) TACI

TACI can bind both BAFF and APRIL and is involved in regulating B-cell activation, immunoglobulin class switching, and plasma cell differentiation. TACI is stage-dependent and context-dependent, and it may display different functions at different stages of B-cell differentiation.

(4) BCMA

BCMA is mainly associated with plasma cell survival and can bind BAFF and APRIL. Compared with BAFF-R, which is more focused on mature B-cell survival, BCMA is more often used to understand plasma cell maintenance, antibody production, and mechanisms of plasma cell-related diseases.

2.2 Effects of BAFF Signaling on B-Cell Fate

(1) Peripheral B-cell survival

BAFF can enhance peripheral B-cell survival and promote the differentiation of transitional B cells into mature B cells. Under normal conditions, this process helps maintain B-cell numbers and humoral immune function. When BAFF signaling is excessively strong, abnormal B cells may evade negative selection.

(2) Retention of autoreactive B cells

Autoreactive B cells normally require strict selection and elimination. Elevated BAFF levels increase the B-cell survival threshold, allowing some low-affinity autoreactive B cells to persist and thereby increasing the risk of autoantibody production and autoimmune responses.

(3) Plasma cell and antibody responses

Through crosstalk with APRIL, TACI, BCMA, and related pathways, BAFF can affect plasmablast- and plasma cell-related responses. This mechanism is closely associated with the persistence of autoantibodies, immune complex deposition, and maintenance of chronic inflammation.

2.3 Mechanism of BAFF-Targeting Antibodies

(1) Neutralization of soluble BAFF

BAFF-targeting monoclonal antibodies can bind soluble BAFF and block its interaction with BAFF-R, TACI, or BCMA, thereby weakening B-cell survival and differentiation support signals. This action does not directly eliminate all B cells, but rather reduces the ability of B-cell populations to obtain survival factors.

(2) Reduction of abnormal B-cell activation

After BAFF is blocked, peripheral B cells, especially cell populations dependent on BAFF for maintenance, may decrease. Because autoreactive B cells lose survival advantage, they are more likely to undergo apoptosis or be restricted by immune homeostatic mechanisms.

(3) Reduction of autoantibody-related responses

BAFF pathway inhibition can indirectly reduce autoantibody production and immune complex-related inflammatory responses. This process usually occurs gradually and depends on the B-cell renewal cycle, plasma cell dependence, and the half-life of existing antibodies.

Table 2 Core Molecules and Functions of the BAFF Pathway

Molecule	Type	Main Expression or Target Object	Immune Function
BAFF / BLyS	Soluble or membrane-bound ligand	B-cell-related lineages	Promotes B-cell survival, maturation, and differentiation
BAFF-R	Receptor	Mature B cells	Maintains peripheral B-cell survival
TACI	Receptor	Activated B cells, plasmablasts	Regulates class switching, B-cell activation, and plasma cell differentiation
BCMA	Receptor	Plasma cells, plasmablasts	Maintains plasma cell survival and antibody responses
APRIL	Related ligand	B-cell and plasma cell-related lineages	Regulates humoral immunity together with TACI and BCMA

3 Composition and Mechanism of the PD-1 Pathway

3.1 PD-1 and Its Ligands

(1) PD-1

PD-1 is mainly expressed on activated T cells and can also be found on some B cells, NK cells, and myeloid cells. PD-1 expression after short-term T-cell activation is part of normal negative feedback regulation. Under persistent antigen stimulation, long-term high PD-1 expression is often associated with T-cell exhaustion.

(2) PD-L1

PD-L1 can be expressed by antigen-presenting cells, tumor cells, endothelial cells, and various inflammatory tissue cells. Inflammatory factors, especially interferon-related signaling, can induce PD-L1 upregulation, creating a local immunosuppressive environment in tissues.

(3) PD-L2

PD-L2 has a relatively narrower expression range and is mainly found on dendritic cells, macrophages, and some tissue cells. Its function is also related to PD-1-mediated inhibitory signaling, but its degree of contribution varies across diseases and tissue contexts.

3.2 Effects of PD-1 Signaling on T-Cell Function

(1) Inhibition of TCR signaling

After PD-1 binds PD-L1 or PD-L2, it can recruit phosphatases through intracellular inhibitory domains and reduce the strength of TCR- and CD28-related signaling. As a result, the T-cell activation threshold increases, proliferation decreases, and effector function becomes restricted.

(2) Reduction of effector factors

When PD-1 signaling is enhanced, T cells may show decreased ability to secrete effector factors such as IL-2, IFN-γ, and TNF-α, and the release of cytotoxic molecules may also weaken. This state helps limit excessive immune injury, but it may also weaken antitumor immunity.

(3) Formation of T-cell exhaustion

In tumors or chronic infection, persistent antigen stimulation promotes T-cell exhaustion. Exhausted T cells usually show upregulation of inhibitory receptors such as PD-1, LAG-3, TIM-3, and TIGIT, accompanied by reduced metabolic function and killing capacity.

3.3 Mechanism of PD-1/PD-L1 Antibodies

(1) Release of inhibitory signaling

PD-1 antibodies can block the interaction between PD-1 and PD-L1/PD-L2, while PD-L1 antibodies block the interaction between PD-L1 and PD-1. Both can reduce inhibitory signal input and allow T cells to partially regain activation and effector function.

(2) Restoration of antitumor immunity

In the tumor microenvironment, PD-1/PD-L1 blockade can enhance tumor-specific T-cell proliferation, cytokine release, and cytotoxicity, thereby promoting tumor cell clearance. Its effect depends on tumor antigen load, T-cell infiltration status, and the immune microenvironment.

(3) Induction of immune-related responses

The PD-1 pathway itself participates in maintaining peripheral immune tolerance. After blockade of this pathway, immune-related inflammatory reactions may occur in some patients or experimental models, involving tissues such as skin, intestine, liver, endocrine organs, and lung. Therefore, PD-1 pathway blockade is essentially immune function release rather than a single antitumor toxic effect.

Table 3 Core Molecules and Functions of the PD-1 Pathway

Molecule	Type	Main Expressing Cells	Immune Function
PD-1	Inhibitory receptor	Activated T cells, exhausted T cells, some B cells and NK cells	Inhibits TCR/CD28 signaling and restricts effector function
PD-L1	Ligand	Tumor cells, antigen-presenting cells, tissue cells	Mediates immune suppression and tumor immune escape
PD-L2	Ligand	Dendritic cells, macrophages, some tissue cells	Participates in PD-1-mediated negative regulation
TCR/CD28	Activation signaling axis	T cells	Provides T-cell recognition and costimulatory signals
IFN-γ-related signaling	Upstream inducing factor	T cells and tissue microenvironment	Can induce PD-L1 expression and form feedback immune regulation

4 Mechanistic Differences Between the BAFF and PD-1 Pathways

4.1 Differences in Target Cells

(1) BAFF mainly acts on the B-cell lineage

The core target cells of the BAFF pathway are B cells and their differentiation-related lineages. It mainly affects B-cell survival, maturation, class switching, plasma cell maintenance, and antibody responses, making it more suitable for analyzing humoral immune abnormalities.

(2) PD-1 mainly acts on T-cell effector function

The core targets of the PD-1 pathway are activated T cells and exhausted T cells. It mainly affects the T-cell activation threshold, cytotoxic activity, cytokine production, and antitumor immune effects, making it more suitable for analyzing cellular immune suppression.

(3) Crosstalk within the immune network

BAFF and PD-1 are not completely independent. B cells can act as antigen-presenting cells and influence T-cell responses, while T cells can also affect B-cell differentiation through helper signals. In autoimmune diseases and tumor immunity, B cells and T cells often participate together in pathological processes, but the main intervention level of the two pathways is different.

4.2 Differences in Therapeutic Purpose

(1) BAFF blockade reduces abnormal immune activity

The goal of BAFF blockade is to reduce the survival advantage of abnormal B cells, thereby decreasing autoantibody production and immune complex-related inflammation. Its therapeutic logic is closer to reducing abnormal humoral immune responses.

(2) PD-1 blockade enhances immune effector function

The goal of PD-1 blockade is to release T-cell inhibition and restore antigen-specific T-cell effector function. Its therapeutic logic is closer to restoring or enhancing antitumor cellular immune responses.

(3) Different risk profiles

Excessive BAFF inhibition may affect normal B-cell immunity and antibody responses, while excessive PD-1 blockade may disrupt peripheral immune tolerance and induce immune-related inflammation. Their safety concerns are different and should not be evaluated using the same immunosuppressive standard.

Table 4 Mechanistic Comparison Between BAFF Blockade and PD-1 Blockade

Comparison Dimension	BAFF Pathway Blockade	PD-1 Pathway Blockade
Main target cells	B cells and plasmablast-related lineages	Activated T cells and exhausted T cells
Main pathological link	Abnormal B-cell survival and autoantibody production	T-cell inhibition and tumor immune escape
Antibody mode of action	Neutralizes BAFF or blocks BAFF-related signaling	Blocks the interaction between PD-1 and PD-L1/PD-L2
Immune outcome	Reduces abnormal humoral immune responses	Enhances T-cell effector function
Main application direction	Autoimmune diseases and abnormal B-cell activation	Tumor immunotherapy
Main safety concerns	Reduced B-cell function and weakened antibody responses	Immune-related inflammation and autoimmune-like reactions

5 Significance of the BAFF Pathway in Autoimmune Diseases

5.1 Autoantibody Production

(1) Altered B-cell selection pressure

Under normal conditions, autoreactive B cells are eliminated, anergized, or functionally restricted during development and maturation. When BAFF levels rise, the B-cell survival threshold decreases, and some autoreactive B cells may gain opportunities for sustained survival.

(2) Formation of autoantibodies

After further activation, autoreactive B cells can differentiate into plasmablasts or plasma cells and produce autoantibodies. Autoantibodies can directly bind tissue antigens or form immune complexes, triggering complement activation and inflammatory cell infiltration.

(3) Maintenance of chronic inflammation

The BAFF pathway affects not only B-cell numbers but also the persistence of humoral immune responses. In systemic autoimmune diseases, excessive BAFF activation can form positive feedback with type I interferons, TLR signaling, and tissue inflammation.

5.2 Features of BAFF-Targeted Intervention

(1) Pace of onset

BAFF blockade usually works gradually by changing the B-cell survival environment. Therefore, its immunological effects are often related to B-cell subset renewal, antibody half-life, and inflammatory burden, and do not necessarily manifest as rapid suppression of inflammation.

(2) Differences among cell subsets

Different B-cell subsets differ in their dependence on BAFF. Peripheral mature B cells and some autoreactive B cells are more dependent on BAFF, whereas long-lived plasma cells may rely more on APRIL, BCMA, and the bone marrow microenvironment.

(3) Combined mechanisms

For diseases highly dependent on autoantibodies, BAFF blockade alone may be insufficient to rapidly remove existing antibodies. If the pathological response is jointly driven by plasma cells, complement, or Fc receptors, therapeutic strategies need to be understood from multiple mechanistic levels.

Table 5 BAFF Pathway-Related Disease Mechanisms and Intervention Focus

Pathological Link	Role of the BAFF Pathway	Intervention Significance	Interpretation Indicators
B-cell survival	Provides peripheral B-cell survival signals	Reduces maintenance of abnormal B cells	Changes in B-cell subsets
Autoreactive B cells	Increases survival probability of abnormal B cells	Reduces the basis of autoimmune responses	Changes in autoantibody profiles
Plasmablast differentiation	Promotes continuation of humoral immune responses	Reduces pressure of antibody production	Plasmablast proportion
Immune complex inflammation	Indirectly promotes autoantibody-related inflammation	Reduces immune complex burden	Complement levels and inflammatory indicators
Chronic inflammatory amplification	Interacts with IFN and TLR signaling	Blocks B cell–inflammation positive feedback	Disease activity indicators

6 Significance of the PD-1 Pathway in Tumor Immunity

6.1 Tumor Immune Escape

(1) Tumor PD-L1 expression

Tumor cells can upregulate PD-L1 expression through genetic alterations, inflammatory factor induction, or microenvironmental adaptation. After PD-L1 binds PD-1 on T cells, it weakens the T-cell response to tumor antigens.

(2) T-cell exhaustion

Persistent tumor antigen exposure leads to long-term T-cell stimulation and consequently an exhaustion-like state. These T cells do not completely lose function, but their proliferation, killing capacity, and cytokine secretion are significantly restricted.

(3) Immunosuppressive microenvironment

The PD-1 pathway often coexists with regulatory T cells, myeloid-derived suppressor cells, immunosuppressive cytokines, and metabolic suppression. Whether PD-1 blockade produces an effective response depends on whether the tumor tissue contains a pool of T cells that can be reactivated.

6.2 Features of PD-1-Targeted Intervention

(1) Dependence on pre-existing immune responses

PD-1/PD-L1 antibodies mainly release inhibition of existing T-cell responses. Therefore, they depend more on tumor antigen presentation, T-cell infiltration, and an inflamed microenvironment. If tumor tissue lacks T-cell infiltration, PD-1 blockade alone may be insufficient to generate a strong response.

(2) Durability of response

Once antitumor T cells are reactivated, some patients or models may develop relatively durable immune control. This feature is related to T-cell memory responses, sustained antigen surveillance, and tumor immune editing.

(3) Immune-related adverse reactions

The PD-1 pathway participates in maintaining immune tolerance in peripheral tissues. After blockade, autoimmune-like inflammation may occur, indicating that this pathway plays a balancing role between antitumor immunity and normal tissue protection.

Table 6 PD-1 Pathway-Related Tumor Immune Mechanisms and Intervention Focus

Pathological Link	Role of the PD-1 Pathway	Result After Blockade	Interpretation Indicators
T-cell exhaustion	Inhibits TCR/CD28 signaling	Restores partial effector function	Proportion of PD-1-high T cells
Tumor immune escape	PD-L1 suppresses T-cell attack	Enhances antitumor killing	PD-L1 expression and T-cell infiltration
Cytokine production	Reduces effector factors such as IFN-γ and IL-2	Enhances inflammatory antitumor response	IFN-γ-related gene signatures
Immune microenvironment	Acts together with Tregs and myeloid suppression	Improves local immunosuppression	CD8/Treg ratio and myeloid cell status
Immune tolerance	Limits inflammation in normal tissues	May cause immune-related inflammation	Tissue inflammation and autoimmune-like indicators

7 Potential Crosstalk Between the BAFF and PD-1 Pathways

7.1 B-Cell and T-Cell Interactions

(1) Antigen presentation

B cells not only produce antibodies but can also act as antigen-presenting cells to participate in T-cell activation. Enhanced BAFF-driven B-cell survival may alter the antigen-presenting cell pool and the strength of T-cell helper responses.

(2) Follicular helper T cells

Tfh cells support B-cell germinal center responses and antibody affinity maturation through signals such as IL-21 and CD40L. BAFF pathway abnormalities may work together with the Tfh-B cell axis to promote autoantibody production.

(3) Tumor-associated B cells

In some tumors, B cells may participate in antitumor antibody responses and tertiary lymphoid structure formation. In other contexts, B cells may also have immunosuppressive functions. Therefore, the BAFF and PD-1 pathways may have indirect crosstalk in tumor immunity, but they are not the same regulatory axis.

7.2 Autoimmunity and Immune Checkpoint Therapy

(1) Autoimmune-like reactions after immune checkpoint release

PD-1 blockade may induce or aggravate autoimmune-like inflammation, indicating that T-cell checkpoints are closely related to self-tolerance. If an individual already has abnormal B-cell activation or an autoantibody background, immune activation may lead to more complex immune responses.

(2) BAFF and immune tolerance

Elevated BAFF levels can lower the threshold for B-cell tolerance, while insufficient PD-1 signaling can lower the threshold for T-cell tolerance. The two pathways influence autoimmune risk from the levels of humoral immunity and cellular immunity, respectively.

(3) Significance of combined research

The relationship between BAFF and PD-1 pathways has research value in autoimmune diseases with tumors, autoimmune-like adverse reactions after immune checkpoint therapy, or tumor microenvironments with significant B-cell participation. However, therapeutically, the two pathways are not simply combined; strategies must be carefully designed according to disease mechanisms.

Table 7 Understanding Crosstalk Between the BAFF and PD-1 Pathways

Crosstalk Level	BAFF-Related Role	PD-1-Related Role	Mechanistic Significance
Immune tolerance	Affects survival of autoreactive B cells	Restricts autoreactive T-cell effector function	Jointly maintains the boundary of self-tolerance
Antigen presentation	B cells can present antigens	T cells receive antigen stimulation and are regulated	Influences T-B cell interactions
Autoimmunity	Promotes autoantibody-related responses	Suppresses or releases T-cell-mediated inflammation	Determines autoimmune risk
Tumor immunity	B cells may participate in antitumor or immunosuppressive effects	T-cell effector function is restricted by PD-1	Influences the complexity of the tumor microenvironment
Therapeutic strategy	Mainly reduces abnormal B-cell activation	Mainly restores T-cell effector function	Different directions of action; not directly comparable

8 Evaluation Points in Experiments and Drug Development

8.1 Evaluation Indicators for the BAFF Pathway

(1) Ligand and receptor expression

The expression levels of BAFF, BAFF-R, TACI, BCMA, and APRIL can be used to assess pathway activation status. In different samples, soluble BAFF, membrane-bound BAFF, and receptor-positive B-cell subsets should be distinguished.

(2) Changes in B-cell subsets

In BAFF blockade research, changes in peripheral mature B cells, transitional B cells, memory B cells, plasmablasts, and plasma cells are important. Different subsets vary in their dependence on BAFF, and results need to be interpreted in a stratified manner.

(3) Antibody and complement indicators

Autoantibody titers, total immunoglobulin levels, complement consumption, and immune complex-related indicators can be used to evaluate the effect of BAFF pathway blockade on humoral immune pathology.

8.2 Evaluation Indicators for the PD-1 Pathway

(1) PD-1/PD-L1 expression

The proportion of PD-1-positive T cells, PD-L1 expression intensity, and spatial distribution are important indicators for analyzing activation of this pathway. Simple expression positivity does not necessarily indicate treatment response and should be interpreted together with T-cell infiltration and functional status.

(2) Recovery of T-cell function

After PD-1 blockade, T-cell proliferation, IFN-γ production, Granzyme B expression, cytotoxic activity, and clonal expansion can be measured. Functional recovery better reflects the effect of pathway blockade than changes in surface markers alone.

(3) Tumor microenvironment features

CD8+ T-cell infiltration, Treg proportion, myeloid suppressor cells, antigen presentation capacity, and inflammatory gene signatures can all affect the outcome of PD-1 pathway blockade. Mechanistic studies should not examine PD-1 or PD-L1 alone.

8.3 Product Selection Related to the BAFF and PD-1 Pathways

Product Category	Cat. No.	Product Name	Target / Pathway	Specification / Grade	Applicable Research Direction / Use
BAFF-targeting therapeutic antibody	Ab170933	Belimumab (anti-TNFSF13B)	BAFF / BLyS / TNFSF13B	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA	BAFF pathway blockade, inhibition of B-cell survival signaling, autoimmune disease and autoantibody-related mechanism research
BAFF-targeting therapeutic antibody	Ab175663	Tabalumab (anti-BAFF)	BAFF	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA	BAFF neutralization, B-cell activation, and humoral immune abnormality research
BAFF-R-targeting therapeutic antibody	Ab176090	Ianalumab (anti-TNFRSF13C)	BAFF-R / TNFRSF13C	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA	BAFF-R blockade, regulation of B-cell survival receptors, and B-cell targeting in autoimmune research
BAFF detection antibody	Ab090522	BAFF Antibody	BAFF	ExactAb™, Validated, 1.0 mg/mL	BAFF expression detection; suitable for method development in WB, IHC, IF, ELISA, or flow cytometry
BAFF recombinant protein	rp329686	Recombinant Human BAFF Protein	BAFF	≥90%(SDS-PAGE)	BAFF receptor binding assays, antibody screening, in vitro stimulation, and standard research
BAFF recombinant protein	rp329439	Recombinant Human BAFF Protein	BAFF	≥95%(SDS-PAGE)	BAFF-BAFFR/TACI/BCMA binding studies and in vitro functional experiments
BAFF recombinant protein	rp169674	Recombinant Human BAFF/BLyS/TNFSF13B Protein	BAFF / BLyS / TNFSF13B	Carrier Free,Bioactive,ActiBioPure™,High Performance,PBS Only,≥90%(SDS-PAGE),See COA	BAFF pathway functional assays, antibody blockade validation, and B-cell survival signaling research
Mouse BAFF recombinant protein	rp329794	Recombinant Mouse BAFF Protein	Mouse BAFF	≥90%(SDS-PAGE)	BAFF signaling research in mouse models, B-cell functional stimulation, and species-matched experiments
BAFF-R recombinant protein	rp143136	Recombinant Human BAFFR/TNFRSF13C Protein	BAFF-R / TNFRSF13C	Animal Free,Carrier Free,Bioactive,ActiBioPure™,Azide Free,PBS Only,≥95%(SDS-PAGE)	BAFF-BAFFR binding assays, receptor-blocking antibody screening, and BAFF-R pathway research
BAFF ELISA kit	H1127430	Human BAFF/BLyS/TNFSF13B ELISA Kit	BAFF / BLyS / TNFSF13B	Bioactive, for enzyme immunoassay(ELISA), for ELISA	Detection of BAFF levels in human serum, plasma, or cell culture supernatant
BAFF ELISA kit	EJ1513420	Human B-Cell Activating Factor (BAFF) ELISA Kit	BAFF	BioReagent	Detection of BAFF levels in human samples; suitable for autoimmune and B-cell activation research
BAFF ELISA kit	EJ1512462	Mouse B-Cell Activating Factor (BAFF/CD257) ELISA Kit	Mouse BAFF / CD257	BioReagent	Detection of BAFF levels in mouse models; suitable for autoimmune animal experiments
BAFF-R ELISA kit	EJ1513422	Human B-Cell Activation Factor Receptor (BAFFR) ELISA Kit	BAFF-R	BioReagent	Detection of BAFFR levels in human samples; supports evaluation of the BAFF receptor axis
BAFF-R ELISA kit	H1510092	Human BAFFR/TNFRSF13C ELISA Kit	BAFFR / TNFRSF13C	BioReagent	Detection of human BAFFR/TNFRSF13C; suitable for B-cell receptor pathway research
BAFF-R ELISA kit	M1509947	Mouse BAFFR/TNFRSF13C ELISA Kit	Mouse BAFFR / TNFRSF13C	BioReagent	Detection of mouse BAFFR; suitable for BAFF-R-related animal model studies
BAFF gene intervention	T1475885	TNFSF13B Human Pre-designed siRNA Set A	TNFSF13B / BAFF		BAFF gene knockdown, pathway functional validation, and cellular model mechanism research
BAFF-R gene intervention	T1487305	TNFRSF13C Human Pre-designed siRNA Set A	TNFRSF13C / BAFF-R		BAFF-R gene knockdown and validation of receptor-dependent signaling
BAFF/APRIL axis detection antibody	Ab130124	TACI Antibody	TACI / TNFRSF13B	Validated, 1.0 mg/mL	TACI expression detection; suitable for BAFF/APRIL receptor axis, B-cell activation, and class switching research
APRIL detection antibody	Ab089395	Recombinant APRIL/TNFSF13 Antibody	APRIL / TNFSF13	Recombinant, ExactAb™, Validated, See COA	APRIL expression detection; suitable for BAFF/APRIL crosstalk pathway research
APRIL-targeting therapeutic antibody	Ab176084	Sibeprenlimab (anti-TNFSF13)	APRIL / TNFSF13	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA	APRIL blockade, plasma cell maintenance, and extended BAFF/APRIL axis mechanism research
APRIL ELISA kit	EJ1514683	Human Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13) ELISA Kit	APRIL / TNFSF13	BioReagent	Detection of APRIL levels in human samples; suitable for BAFF/APRIL axis analysis
APRIL ELISA kit	EJ1513092	Mouse Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13) ELISA Kit	Mouse APRIL / TNFSF13	BioReagent	Detection of APRIL in mouse samples; suitable for animal model mechanism research
BCMA detection antibody	Ab090856	BCMA Antibody	BCMA / TNFRSF17	ExactAb™, Validated, Carrier Free, 1.0 mg/mL	BCMA expression detection; suitable for plasma cells, myeloma cells, and BAFF/APRIL-BCMA axis research
BCMA detection antibody	Ab090857	BCMA/CD269 Mouse mAb	BCMA / CD269	Carrier Free, ExactAb™, Validated, See COA	BCMA/CD269 detection; suitable for plasma cell phenotype and BCMA pathway research
BCMA peptide	B1424223	BCMA72-80	BCMA		BCMA-related immune recognition, epitope research, or method development
BCMA-targeting antibody	Ab170526	Belantamab (anti-TNFRSF17)	BCMA / TNFRSF17	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA	BCMA-targeting mechanisms, plasma cell-related diseases, and BCMA pathway research
BCMA antibody-drug conjugate	Ab175467	Belantamab mafodotin (anti-BCMA)	BCMA	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥90%(SDS-PAGE&SEC-HPLC), See COA	BCMA-targeted therapy mechanisms, plasma cell clearance, and antibody-drug conjugate research
BCMA/CD3 bispecific antibody	Ab182996	Linvoseltamab (anti-BCMA&CD3)	BCMA / CD3	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥90%(SDS-PAGE&SEC-HPLC), See COA	T-cell redirection, BCMA-positive cell killing, and plasma cell-related immunotherapy research
CD3/BCMA bispecific antibody	Ab175669	Teclistamab (anti-CD3&BCMA)	CD3 / BCMA	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥90%(SDS-PAGE&SEC-HPLC), See COA	BCMA-positive plasma cell targeting, T cell-mediated killing, and bispecific antibody mechanism research
BCMA recombinant protein	rp169554	Recombinant Human BCMA/TNFRSF17 Protein	BCMA / TNFRSF17	Animal Free,Carrier Free,Bioactive,ActiBioPure™,Fc tag,PBS Only,≥90%(SDS-PAGE)	BAFF/APRIL-BCMA binding assays, antibody screening, and plasma cell pathway research
BCMA recombinant protein	rp329478	Recombinant Human TNFRSF17 Protein	TNFRSF17 / BCMA	≥90%(SDS-PAGE)	BCMA-related receptor binding, antibody screening, and standard research
BCMA ELISA kit	H1509943	Human BCMA/TNFRSF17 ELISA Kit	BCMA / TNFRSF17	BioReagent	Human BCMA detection; suitable for plasma cell activation and downstream BAFF/APRIL axis analysis
BCMA ELISA kit	EJ1514676	Human Tumor Necrosis Factor Receptor Superfamily, Member 17 (TNFRSF17/BCMA) ELISA Kit	TNFRSF17 / BCMA	BioReagent	Detection of human TNFRSF17/BCMA levels; suitable for plasma cell-related research
BCMA ELISA kit	M1509949	Mouse BCMA/TNFRSF17 ELISA Kit	Mouse BCMA / TNFRSF17	BioReagent	Mouse BCMA detection; suitable for plasma cell pathway analysis in animal models
BCMA gene intervention	T1471481	TNFRSF17 Human Pre-designed siRNA Set A	TNFRSF17 / BCMA		BCMA gene knockdown and functional validation of plasma cell receptor pathways
BCMA knockout cell lysate	P751165	pLenti-TNFRSF17-sgRNA	TNFRSF17 / BCMA		BCMA antibody specificity validation, protein detection control, and knockout model research
BCMA knockout cell lysate	P751166	pLenti-TNFRSF17-sgRNA	TNFRSF17 / BCMA		BCMA-related RNA detection, knockout controls, and expression validation
PD-1-targeting therapeutic antibody	N411994	Nivolumab (anti-PD-1)	PD-1	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA	PD-1 blockade, reversal of T-cell exhaustion, and tumor immune checkpoint research
PD-1-targeting therapeutic antibody	P411997	Pembrolizumab (anti-PD-1)	PD-1	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA	PD-1/PD-L1 axis blockade, restoration of antitumor T-cell function, and immunotherapy mechanism research
PD-1-targeting therapeutic antibody	C412010	Cemiplimab (anti-PD-1)	PD-1	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA	PD-1 blockade, T-cell effector function restoration, and tumor immunity research
PD-1-targeting therapeutic antibody	Ab175513	Dostarlimab (anti-PD-1)	PD-1	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA	Blocking PD-1 interaction with PD-L1/PD-L2 and immune checkpoint research
PD-1-targeting therapeutic antibody	Ab182801	Toripalimab (anti-PD-1)	PD-1	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA	PD-1 pathway blockade, tumor immunity, and T-cell function research
PD-1-targeting therapeutic antibody	Ab169307	Sintilimab (anti-PD-1)	PD-1	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA	PD-1 immune checkpoint blockade and antitumor immunity research
PD-L1-targeting therapeutic antibody	A411996	Atezolizumab (anti-PD-L1)	PD-L1	Animal Free, ≥95%, See COA	PD-L1 blockade, tumor cell immune escape, and T-cell effector restoration research
PD-L1-targeting therapeutic antibody	D412005	Durvalumab (anti-PD-L1)	PD-L1	Carrier Free, Recombinant, ExactAb™, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA	Blocking PD-L1 interaction with PD-1/CD80 and tumor immune microenvironment research
PD-L1-targeting therapeutic antibody	A412006	Avelumab (anti-PD-L1)	PD-L1	Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA	PD-L1 blockade, ADCC-related antitumor effects, and immune checkpoint research

9 Result Interpretation and Application Boundaries

9.1 Interpretation Boundaries of the BAFF Pathway

(1) Elevated BAFF does not equal a single driving factor

Elevated BAFF indicates enhanced B-cell survival factors, but autoimmune diseases usually also involve T-cell help, type I interferons, TLR signaling, complement activation, and tissue injury. BAFF level alone cannot fully explain disease activity.

(2) B-cell reduction does not equal rapid disappearance of autoantibodies

After BAFF blockade, some B-cell subsets may decrease, but antibodies produced by long-lived plasma cells may persist for a long time. Therefore, there may be a time lag between changes in B-cell numbers and reduction of autoantibodies.

(3) BAFF blockade is not broad-spectrum immune clearance

BAFF-targeting strategies mainly reduce BAFF-dependent B-cell survival support. They are not equivalent to CD20 antibody-mediated B-cell depletion, nor are they equivalent to direct plasma cell elimination.

9.2 Interpretation Boundaries of the PD-1 Pathway

(1) PD-L1 positivity does not necessarily indicate effective response

PD-L1 expression may suggest pathway involvement, but treatment response also depends on tumor antigens, T-cell infiltration, antigen presentation capacity, and other immunosuppressive mechanisms. PD-L1-negative samples may not be completely nonresponsive.

(2) T-cell activation does not equal tumor control

PD-1 blockade can restore partial T-cell function, but tumors may still evade immune attack through antigen loss, MHC downregulation, myeloid suppression, TGF-β enrichment, or metabolic inhibition.

(3) Immune activation carries the risk of tolerance disruption

PD-1 pathway blockade enhances antitumor immunity while potentially reducing peripheral immune tolerance. Both efficacy and immune-related inflammatory risk should be considered in mechanistic research and clinical translation.

Table 8 Comparison of Application Boundaries Between the BAFF and PD-1 Pathways

Interpretation Issue	BAFF Pathway	PD-1 Pathway
Does target elevation equal disease driving?	Not necessarily; must be combined with B-cell subsets and autoantibodies	Not necessarily; must be combined with T-cell infiltration and functional status
Is pathway blockade rapidly effective?	Usually depends on B-cell renewal and antibody half-life	May rapidly restore partial T-cell function, but efficacy depends on the microenvironment
Main efficacy assessment	B-cell subsets, autoantibodies, complement, and disease activity	T-cell function, tumor burden, immune infiltration, and inflammatory responses
Main safety concern	Reduced humoral immunity, infection risk, weakened antibody response	Immune-related adverse events and autoimmune-like inflammation
Can they be simply combined?	Must be judged based on the degree of B-cell-driven pathology	Must be judged based on tumor immune status and autoimmune risk

The BAFF pathway and the PD-1 pathway represent humoral immune regulation and cellular immune checkpoint regulation, respectively, in therapeutic monoclonal antibody-mediated immune modulation. BAFF-targeting antibodies weaken B-cell survival signals, thereby reducing autoreactive B cells and autoantibody-related pathological responses. PD-1/PD-L1-targeting antibodies release T-cell inhibition and restore antitumor immune effects. Their shared feature is that both occupy key nodes in immune homeostasis regulation, while their differences lie in target cells, immune direction, disease application scenarios, and safety boundaries.

For more related articles, please see below:

[1] PD-1/PD-L1 Signaling Pathway